Advertisement Pharmaceutical Business review - Page 346 of 5280 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 7, 2026

EC approves AbbVie’s Tepkinly combination for follicular lymphoma

The European Commission (EC) has granted marketing authorisation for AbbVie’s Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (Tepkinly + R²) for adult patients with relapsed or refractory follicular lymphoma.

Epcoritamab is co-developed by AbbVie and Genmab. Credit: © AbbVie Inc. All rights reserved.